croaie smgt glp 1 nano microneedle patch 𝑪𝒓𝒐𝒂𝒊𝒆® 𝑺𝑴𝑮𝑻-𝑮𝑳𝑷-1 𝑵𝒂𝒏𝒐 𝑴𝒊𝒄𝒓𝒐𝒏𝒆𝒆𝒅𝒍𝒆 𝑷𝒂𝒕𝒄𝒉 Croaie Nano Microneedle Patch Review

There is no accumulation of the drug at steady state

Emerging evidence indicates that lipid traits may have a role in DR as well, though work to understand this mechanism is still being conducted [79]

doi: 10.1016/j.cmet.2019.11.016, 57

Martin Holst Lange, Novo Nordisks Chief Scientific Officer, put it bluntly: Wegovy is now uniquely positioned as the first and only GLP1 treatment approved for MASH, complementing the already proven weight loss, cardiovascular benefits and extensive body of evidence linked to semaglutide Living with liver disease will still require lifestyle changes

Volkow ND, Xu R

The abstract of the published study indicates that it works, but the results tell a different story